Access Infinity closely analysed the updates on the EU Pharma package, a sweeping legislative reform designed to reshape pharmaceutical regulation, access, and incentives across Member States.
EU Pharma Package Enters Trilogues: A Turning Point for Access, Exclusivity and Innovation
On June 4, 2025, after nearly two years of legislative debate, the Council of the European Union adopted its position on the EU Pharma Package, the most ambitious overhaul of EU pharmaceutical legislation in over 20 years. Comprising a Directive and a Regulation, the Package aims to update the outdated framework (Directive 2001/83/EC, Regulation 726/2004) and unify orphan and paediatric medicine laws under one roof.
Diverging views of the Council, Parliament, and Commission
As part of the broader pharmaceutical reform, the Council, Parliament, and Commission proposed differing approaches to regulatory data protection and market exclusivity. While technical elements like transferable vouchers and transition timelines were addressed, Member States also voiced diverging views. Countries with major pharmaceutical industries such as Germany, France, Italy, Denmark, and Sweden opposed modulated data protection tied to fulfilling public health conditions, citing concerns over innovation incentives. In contrast, Malta, Estonia, Cyprus, Portugal, and the Czech Republic raised issues around equitable access. Malta voted against the Council’s position, criticising insufficient access obligations and the extension of data protection.
Looking Ahead: From Debate to Direction
While there are clear disagreements on some key topics, there is also acknowledgement of shared goals across institutions. The pharmaceutical industry continues to emphasize the importance of finding a balanced approach between improving access to medicines, fostering innovation, and maintaining competitiveness.
Now, with trilogue negotiations officially launched on 17 June 2025, the EU institutions are working to align on the final text. While the first trilogue was largely procedural, progress will pick up in September under Denmark’s presidency, as the window to finalise the reform by the end of 2025 narrows.
If trilogue agreements solidify in early 2026, rollout may begin by 2027–2029, depending on the transition timelines.
Strategic Alignment Needed Across Stakeholders: Navigating Emerging EU Regulatory Shifts
The EU Pharma Package is no longer theoretical. Trilogues have begun. Global regulatory, market access and pricing professionals should proactively evaluate how new obligations and incentives will impact launch planning, exclusivity strategies, and regulatory engagement at both EU and Member State levels.
Key Next Steps for Pharma Stakeholders
- Scenario modelling around access-linked exclusivity as they prepare for more complex market entry strategies involving such scenarios
- Communication with national bodies as country-level rules take shape thereby anticipating national-level variation in enforcement and impact
- Work with internal stakeholders to assess portfolio impact, particularly on orphan drugs, antimicrobials, and late-launch products
- Stay engaged as September 2025 trilogues resume: key provisions may likely shift
Click here to learn about Access Infinity’s Digital + Consulting Suite of Solutions
Authored by
Nikhil Taxak, Ph. D, APAC Head, Pricing and Market Access Data and Analytics*
Sapana Gusain, Associate Analyst, Data Team
David McConkey, Partner
Brett Gardiner, Senior Partner
All authors represent Access Infinity
*Corresponding author: nikhil@accessinfinity.com
